Published in J Agric Food Chem on August 12, 2008
Polysaccharides isolated from Açaí fruit induce innate immune responses. PLoS One (2011) 0.94
Exotic Fruits as Therapeutic Complements for Diabetes, Obesity and Metabolic Syndrome. Food Res Int (2011) 0.90
Dietary açai modulates ROS production by neutrophils and gene expression of liver antioxidant enzymes in rats. J Clin Biochem Nutr (2011) 0.88
Transcriptional regulation of anthocyanin biosynthesis in red cabbage. Planta (2009) 0.86
Effects of Açai (Euterpe oleracea Mart.) berry preparation on metabolic parameters in a healthy overweight population: a pilot study. Nutr J (2011) 0.85
Anthocyanins: are they beneficial in treating ethanol neurotoxicity? Neurotox Res (2009) 0.85
Banana by-products: an under-utilized renewable food biomass with great potential. J Food Sci Technol (2012) 0.82
The Chemistry of Gut Microbial Metabolism of Polyphenols. Phytochem Rev (2016) 0.78
Effects of supplementation with acai (Euterpe oleracea Mart.) berry-based juice blend on the blood antioxidant defence capacity and lipid profile in junior hurdlers. A pilot study. Biol Sport (2015) 0.78
Cytotoxic effects of Euterpe oleracea Mart. in malignant cell lines. BMC Complement Altern Med (2014) 0.78
Carbohydrate-Free Peach (Prunus persica) and Plum (Prunus salicina) [corrected] Juice Affects Fecal Microbial Ecology in an Obese Animal Model. PLoS One (2014) 0.77
The safety and pharmacokinetics of cyanidin-3-glucoside after 2-week administration of black bean seed coat extract in healthy subjects. Korean J Physiol Pharmacol (2012) 0.75
Physicochemical properties of dietary phytochemicals can predict their passive absorption in the human small intestine. Sci Rep (2017) 0.75
Açaí Berries Inhibit Colon Tumorigenesis in Azoxymethane/Dextran Sulfate Sodium-Treated Mice. Gut Liver (2016) 0.75
Genetic ancestry in lung-function predictions. N Engl J Med (2010) 3.30
Genome-wide association and large-scale follow up identifies 16 new loci influencing lung function. Nat Genet (2011) 3.03
Standardization of pharmacokinetic/pharmacodynamic (PK/PD) terminology for anti-infective drugs: an update. J Antimicrob Chemother (2005) 2.50
Pharmacokinetic/pharmacodynamic profile of voriconazole. Clin Pharmacokinet (2006) 2.32
Population pharmacokinetics of therapeutic monoclonal antibodies. Clin Pharmacokinet (2010) 2.20
Issues in pharmacokinetics and pharmacodynamics of anti-infective agents: kill curves versus MIC. Antimicrob Agents Chemother (2004) 2.10
Tissue concentrations: do we ever learn? J Antimicrob Chemother (2007) 1.92
Issues in pharmacokinetics and pharmacodynamics of anti-infective agents: distribution in tissue. Antimicrob Agents Chemother (2004) 1.64
Is age-related decline in lean mass and physical function accelerated by obstructive lung disease or smoking? Thorax (2011) 1.60
Immunogenicity to therapeutic proteins: impact on PK/PD and efficacy. AAPS J (2012) 1.58
A microbiological assessment of novel nitrofuranylamides as anti-tuberculosis agents. J Antimicrob Chemother (2008) 1.58
Evaluation of vancomycin dosing regimens in preterm and term neonates using Monte Carlo simulations. Pharmacotherapy (2012) 1.55
Genome-wide joint meta-analysis of SNP and SNP-by-smoking interaction identifies novel loci for pulmonary function. PLoS Genet (2012) 1.52
Moderate consumption of Cabernet Sauvignon attenuates Abeta neuropathology in a mouse model of Alzheimer's disease. FASEB J (2006) 1.49
Genome-wide association studies identify CHRNA5/3 and HTR4 in the development of airflow obstruction. Am J Respir Crit Care Med (2012) 1.49
Protein binding: do we ever learn? Antimicrob Agents Chemother (2011) 1.46
PA-824 exhibits time-dependent activity in a murine model of tuberculosis. Antimicrob Agents Chemother (2010) 1.38
Significance of protein binding in pharmacokinetics and pharmacodynamics. J Pharm Sci (2010) 1.37
How important are gender differences in pharmacokinetics? Clin Pharmacokinet (2002) 1.37
AAPS-FDA workshop white paper: microdialysis principles, application and regulatory perspectives. Pharm Res (2007) 1.35
Total antioxidant activity and fiber content of select Florida-grown tropical fruits. J Agric Food Chem (2006) 1.34
Characterizing the effects of caspofungin on Candida albicans, Candida parapsilosis, and Candida glabrata isolates by simultaneous time-kill and postantifungal-effect experiments. Antimicrob Agents Chemother (2006) 1.34
Concepts and challenges in quantitative pharmacology and model-based drug development. AAPS J (2008) 1.27
Absorption, metabolism, and antioxidant effects of pomegranate (Punica granatum l.) polyphenols after ingestion of a standardized extract in healthy human volunteers. J Agric Food Chem (2006) 1.26
Pharmacokinetic aspects of biotechnology products. J Pharm Sci (2004) 1.25
Pharmacokinetic/pharmacodynamic profile of posaconazole. Clin Pharmacokinet (2010) 1.25
Standardization of pharmacokinetic/pharmacodynamic (PK/PD) terminology for anti-infective drugs. Int J Antimicrob Agents (2002) 1.24
Rational dosing of antibiotics: the use of plasma concentrations versus tissue concentrations. Int J Antimicrob Agents (2002) 1.23
Discovery of novel 2-aryl-4-benzoyl-imidazoles targeting the colchicines binding site in tubulin as potential anticancer agents. J Med Chem (2010) 1.21
Identification of ellagic acid conjugates and other polyphenolics in muscadine grapes by HPLC-ESI-MS. J Agric Food Chem (2005) 1.20
The clinical pharmacokinetics of phosphodiesterase-5 inhibitors for erectile dysfunction. J Clin Pharmacol (2005) 1.20
Duffy antigen modifies the chemokine response in human endotoxemia. Crit Care Med (2008) 1.20
Effect of protein binding on the pharmacological activity of highly bound antibiotics. Antimicrob Agents Chemother (2008) 1.16
Pharmacokinetic/pharmacodynamic evaluation of anti-infective agents. Expert Rev Anti Infect Ther (2005) 1.14
Pharmacokinetic/pharmacodynamic modeling of in vitro activity of azithromycin against four different bacterial strains. Int J Antimicrob Agents (2006) 1.13
The in silico child: using simulation to guide pediatric drug development and manage pediatric pharmacotherapy. J Clin Pharmacol (2009) 1.12
Once-daily tobramycin in cystic fibrosis: better for clinical outcome than thrice-daily tobramycin but more resistance development? J Antimicrob Chemother (2006) 1.12
Pharmacokinetic-pharmacodynamic modelling of antibacterial activity of cefpodoxime and cefixime in in vitro kinetic models. Int J Antimicrob Agents (2005) 1.11
Discovery of novel isoxazolines as anti-tuberculosis agents. Bioorg Med Chem Lett (2007) 1.11
Tobacco smoke exposure induces nicotine dependence in rats. Psychopharmacology (Berl) (2009) 1.11
Hyperforin in St. John's wort drug interactions. Eur J Clin Pharmacol (2006) 1.10
Ertapenem in critically ill patients with early-onset ventilator-associated pneumonia: pharmacokinetics with special consideration of free-drug concentration. J Antimicrob Chemother (2006) 1.09
Population pharmacokinetics of cetuximab in patients with squamous cell carcinoma of the head and neck. J Clin Pharmacol (2008) 1.08
Differences in drug pharmacokinetics between East Asians and Caucasians and the role of genetic polymorphisms. J Clin Pharmacol (2004) 1.07
Comparative pharmacology, bioavailability, pharmacokinetics, and pharmacodynamics of inhaled glucocorticosteroids. Immunol Allergy Clin North Am (2005) 1.07
Pharmacokinetic/pharmacodynamic studies in drug product development. J Pharm Sci (2002) 1.06
Low concentrations of quercetin and ellagic acid synergistically influence proliferation, cytotoxicity and apoptosis in MOLT-4 human leukemia cells. J Nutr (2003) 1.06
Population kinetics, efficacy, and safety of dichloroacetate for lactic acidosis due to severe malaria in children. J Clin Pharmacol (2003) 1.05
Pharmacokinetics and bioavailability of herbal medicinal products. Phytomedicine (2002) 1.04
G2677T and C3435T genotype and haplotype are associated with hepatic ABCB1 (MDR1) expression. J Clin Pharmacol (2006) 1.04
Skin and soft tissue concentrations of tedizolid (formerly torezolid), a novel oxazolidinone, following a single oral dose in healthy volunteers. Int J Antimicrob Agents (2012) 1.03
Carvedilol therapy in pediatric patients with congestive heart failure: a study investigating clinical and pharmacokinetic parameters. Am Heart J (2002) 1.03
Class-dependent relevance of tissue distribution in the interpretation of anti-infective pharmacokinetic/pharmacodynamic indices. Int J Antimicrob Agents (2010) 1.03
Inhaled corticosteroids: past lessons and future issues. J Allergy Clin Immunol (2003) 1.02
Pharmacokinetics of piperacillin-tazobactam: intermittent dosing versus continuous infusion. Int J Antimicrob Agents (2005) 1.02
Identification of brain-targeted bioactive dietary quercetin-3-O-glucuronide as a novel intervention for Alzheimer's disease. FASEB J (2012) 1.01
Heterogeneity in red wine polyphenolic contents differentially influences Alzheimer's disease-type neuropathology and cognitive deterioration. J Alzheimers Dis (2009) 1.01
Soft tissue penetration of cefuroxime determined by clinical microdialysis in morbidly obese patients undergoing abdominal surgery. Int J Antimicrob Agents (2009) 1.01
AAPS-FDA Workshop White Paper: microdialysis principles, application, and regulatory perspectives. J Clin Pharmacol (2007) 1.01
Antitubercular nitrofuran isoxazolines with improved pharmacokinetic properties. Bioorg Med Chem (2012) 1.00
The effect of CYP3A5 and MDR1 polymorphic expression on cyclosporine oral disposition in renal transplant patients. J Clin Pharmacol (2003) 1.00
Chemical composition, antioxidant properties, and thermal stability of a phytochemical enriched oil from Acai (Euterpe oleracea Mart.). J Agric Food Chem (2008) 1.00
Pharmacokinetically-guided lead optimization of nitrofuranylamide anti-tuberculosis agents. AAPS J (2008) 1.00
Açai (Euterpe oleracea Mart.) polyphenolics in their glycoside and aglycone forms induce apoptosis of HL-60 leukemia cells. J Agric Food Chem (2006) 1.00
Importance of relating efficacy measures to unbound drug concentrations for anti-infective agents. Clin Microbiol Rev (2013) 0.99
Development of a safe and effective pediatric dosing regimen for sotalol based on population pharmacokinetics and pharmacodynamics in children with supraventricular tachycardia. J Am Coll Cardiol (2005) 0.98
Pharmacokinetics and pharmacokinetic-pharmacodynamic correlations of therapeutic peptides. Clin Pharmacokinet (2013) 0.98
PK/PD: new insights for antibacterial and antiviral applications. Curr Opin Pharmacol (2008) 0.98
Ertapenem: the new carbapenem 5 years after first FDA licensing for clinical practice. Expert Opin Pharmacother (2007) 0.98
In vitro pharmacodynamic models to determine the effect of antibacterial drugs. J Antimicrob Chemother (2009) 0.98
Population pharmacokinetic model of human insulin following different routes of administration. J Clin Pharmacol (2010) 0.98
Pharmacokinetics and pharmacodynamics of ponesimod, a selective S1P1 receptor modulator, in the first-in-human study. Br J Clin Pharmacol (2013) 0.98
The influence of abdominal visceral fat on inflammatory pathways and mortality risk in obstructive lung disease. Am J Clin Nutr (2012) 0.97
Simulation-based sodium thiosulfate dosing strategies for the treatment of calciphylaxis. Clin J Am Soc Nephrol (2011) 0.97
Role of pharmacokinetics in establishing bioequivalence for orally inhaled drug products: workshop summary report. J Aerosol Med Pulm Drug Deliv (2011) 0.97
Single- and multiple-dose pharmacokinetics of pioglitazone in adolescents with type 2 diabetes. J Clin Pharmacol (2005) 0.97
Clinical pharmacokinetics and pharmacodynamics of tigecycline. Clin Pharmacokinet (2009) 0.96
Risk-benefit value of inhaled glucocorticoids: a pharmacokinetic/pharmacodynamic perspective. J Clin Pharmacol (2004) 0.96
Clinical microdialysis in skin and soft tissues: an update. J Clin Pharmacol (2008) 0.96
Protective effects of standardized pomegranate (Punica granatum L.) polyphenolic extract in ultraviolet-irradiated human skin fibroblasts. J Agric Food Chem (2008) 0.96
Modulation of metoprolol pharmacokinetics and hemodynamics by diphenhydramine coadministration during exercise testing in healthy premenopausal women. J Pharmacol Exp Ther (2005) 0.95
Predictors of mortality in elderly subjects with obstructive airway disease: the PILE score. Ann Epidemiol (2010) 0.95
Anticarcinogenic effects of polyphenolics from mango (Mangifera indica) varieties. J Agric Food Chem (2010) 0.95
Serum concentrations and clinical effects of atorvastatin in patients taking grapefruit juice daily. Br J Clin Pharmacol (2011) 0.94
Population pharmacokinetics and dose simulation of carvedilol in paediatric patients with congestive heart failure. Br J Clin Pharmacol (2007) 0.94
Pharmacometrics as a discipline is entering the "industrialization" phase: standards, automation, knowledge sharing, and training are critical for future success. J Clin Pharmacol (2010) 0.94
Interstitial tissue concentrations of cefpodoxime. J Antimicrob Chemother (2002) 0.93
A simple in vitro PK/PD model system to determine time-kill curves of drugs against Mycobacteria. Tuberculosis (Edinb) (2009) 0.93
How the lung handles drugs: pharmacokinetics and pharmacodynamics of inhaled corticosteroids. Proc Am Thorac Soc (2004) 0.93
Variation of flavonoids and furanocoumarins in grapefruit juices: a potential source of variability in grapefruit juice-drug interaction studies. J Agric Food Chem (2006) 0.93
The Candida albicans phosphatase Inp51p interacts with the EH domain protein Irs4p, regulates phosphatidylinositol-4,5-bisphosphate levels and influences hyphal formation, the cell integrity pathway and virulence. Microbiology (2008) 0.93
Comparison of the pharmacokinetic properties of vancomycin, linezolid, tigecyclin, and daptomycin. Eur J Med Res (2010) 0.93
Feasibility of a breath test for monitoring adherence to vaginal administration of antiretroviral microbicide gels. J Clin Pharmacol (2013) 0.93
Phytochemical composition and pigment stability of Açai (Euterpe oleracea Mart.). J Agric Food Chem (2004) 0.92
Anti-von Willebrand factor aptamer ARC1779 for refractory thrombotic thrombocytopenic purpura. Transfusion (2009) 0.92
A pharmacokinetic/pharmacodynamic mathematical model accurately describes the activity of voriconazole against Candida spp. in vitro. Int J Antimicrob Agents (2008) 0.92